Pipeline

Avanir is innovation.

By focusing on disorders of the central nervous system, we strive to meet the needs of patients with innovative solutions. Below is an overview of our pipeline, updated quarterly.

AVP-825

Acute Migraine in Adolescents
Phase 1(Planned)
Phase 2(Planned)
Phase 3(Planned)
Phase 4

Description/Summary

The objective of the study is to evaluate the safety and efficacy of AVP-825 compared to placebo in the acute treatment of migraine in adolescent patients, 12 through 17 years-of-age.

AVP-786

Agitation in Alzheimer's (US)
Phase 1(Planned)
Phase 2(Planned)
Phase 3(Planned)
Phase 4

Description/Summary

The objectives of the studies are to evaluate the efficacy, safety, and tolerability of AVP-786 compared to placebo, for the treatment of agitation in patients with dementia of the Alzheimer’s type.

Agitation in Alzheimer's (Global)
Phase 1(Planned)
Phase 2(Planned)
Phase 3(Planned)
Phase 4

Description/Summary

The objectives of the studies are to evaluate the efficacy, safety, and tolerability of AVP-786 compared to placebo, for the treatment of agitation in patients with dementia of the Alzheimer’s type.

Negative Symptoms of Schizophrenia
Phase 1(Planned)
Phase 2(Planned)
Phase 3(Planned)
Phase 4

Description/Summary

The objectives of this study are to evaluate the efficacy, safety, and tolerability of AVP-786 as an adjunctive treatment compared with placebo in patients with schizophrenia who have predominantly negative symptoms.

Intermittent Explosive Disorder
Phase 1(Planned)
Phase 2(Planned)
Phase 3(Planned)
Phase 4

Description/Summary

The objectives of the study are to evaluate the efficacy, safety, and tolerability of AVP-786 compared to placebo, for the treatment in patients with Intermittent explosive disorder (IED). 

Traumatic Brain Injury-Neurobehavioral Disinhibition
Phase 1(Planned)
Phase 2(Planned)
Phase 3(Planned)
Phase 4

Description/Summary

The objectives of the study are to evaluate the efficacy, safety, and tolerability of AVP-786 compared to placebo, for the treatment of neurobehavioral disinhibition such as aggression, agitation, and irritability in patients with traumatic brain injury.

Disclaimer

 

Block 4 - Job Block

Unlock the future of CNS treatment

Join our team of Innovators

Avanir employees are a diverse team of dedicated, accomplished professionals united by a common purpose: striving to make a change by developing innovative treatments for central nervous system (CNS) conditions.

View open opportunities at Avanir

Join our team of Innovators